NCT04937543.
Study name | Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID‐19 (TRIVID) |
Methods | Trial design: open‐label, RCT Sample size: 260 Setting: probably inpatient Language: English Number of centres: not reported Type of intervention: treatment |
Participants | Inclusion criteria:
|
Interventions | Intervention group: inhaled beclomethasone (dose not stated) + standard care; beclomethasone/formoterol/glycopyrronium (dose not stated) + standard care Control group: standard care Concomitant therapy: no |
Outcomes | Primary outcome: proportion of participants using health resources 28 days after treatment Secondary outcome: airway obstruction using spirometry 28 days after treatment; small airway obstruction using CT 28 days after treatment |
Starting date | 28 June 2021 |
Contact information | Suzana Minamoto: suzana.tanni@unesp.br Luana Pagan: luanapagan@alunos.fmb.unesp.br |
Notes | Recruitment status: not yet recruiting Prospective completion date: 30 October 2021 Date last update was posted: 30 June 2021 Sponsor/funding: UPECLIN HC FM Botucatu Unesp |